Your session is about to expire
← Back to Search
Study Summary
This trial studies a new oral medicine to treat certain advanced and metastatic cancers in adults. It looks at how safe and effective the medicine is.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer is advanced, cannot be surgically removed, and has RAS or BRAF mutations.My brain metastases are stable and I don't need more steroids for them.
- Group 1: Phase 1 Dose Escalation
- Group 2: Phase 1 Dose Expansion
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this clinical trial currently admit participants?
"Affirmative. According to the clinicaltrials.gov database, this therapeutic trial is currently recruiting participants and was first made public on April 18th 2023. The study requires 140 people from two separate medical sites with an update having been posted as recently as April 24th 2023."
Has the FDA sanctioned Phase 1 Dose Expansion?
"Due to the limited data collected during Phase 1 trials, our team at Power assigned a score of 1 for Dose Expansion's safety and effectiveness."
What is the highest capacity of participants in this medical experiment?
"Affirmative. Clinicaltrials.gov lists this trial as actively recruiting, beginning April 18th 2023 and edited last on the 24th of that same month. 140 individuals will be accepted between two distinct sites for this study's duration."
Share this study with friends
Copy Link
Messenger